Related Experiment Video

Updated: Jul 1, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Strict glycemic targets need not be so strict: a more permissive glycemic range for critically ill children

Kalia Patricia Ulate1, Germano Correia Lima Falcao, Mark Richard Bielefeld

  • 1Department of Pediatrics, Driscoll Children's Hospital, Corpus Christi, TX 78411, USA.

Pediatrics
|September 10, 2008
PubMed

Insights

Postoperative hyperglycemia in children undergoing congenital heart defect surgery is linked to higher mortality. A more permissive blood glucose target reduces hypoglycemia without increasing death rates.

Area of Science:

  • Pediatric critical care medicine
  • Cardiovascular surgery
  • Endocrinology

Background:

  • Hyperglycemia is a common complication in critically ill pediatric patients, particularly after congenital heart defect surgery.
  • The optimal glycemic target in this population remains debated, with concerns about hypoglycemia versus hyperglycemia-related morbidity and mortality.

Purpose of the Study:

  • To investigate the association between postoperative glycemic control and outcomes in pediatric patients undergoing congenital heart defect surgery.
  • To determine if a more permissive glycemic target reduces hypoglycemia incidence without increasing mortality.

Main Methods:

  • Retrospective analysis of 177 pediatric patients undergoing 211 surgical procedures for congenital heart defects.
  • Patients were stratified into glycemic groups: euglycemia, mild, moderate, and severe hyperglycemia.
  • Outcomes were compared between glycemic groups and a permissive target group (90-140 mg/dL).

Main Results:

  • Nonsurvivors exhibited higher peak glucose levels and a longer duration of hyperglycemia in the first 5 postoperative days.
  • Moderate and severe hyperglycemia groups had significantly higher mortality rates compared to euglycemia and permissive target groups.
  • The permissive target group showed a significantly lower incidence of hypoglycemia than the euglycemia group.

Conclusions:

  • Postoperative hyperglycemia is a significant risk factor for increased morbidity and mortality in pediatric patients after congenital heart defect surgery.
  • Implementing a more permissive glycemic target (90-140 mg/dL) is associated with reduced hypoglycemia without adversely affecting mortality rates.
Abstract

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Hypoglycemia01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...